Ovarian cancer screening
- PMID: 12959188
- DOI: 10.1016/s0889-8588(03)00063-7
Ovarian cancer screening
Abstract
In an ongoing effort to design an efficacious, cost-effective ovarian cancer screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as mesothelin and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.
Similar articles
-
Elevation of multiple serum markers in patients with stage I ovarian cancer.J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51. doi: 10.1093/jnci/85.21.1748. J Natl Cancer Inst. 1993. PMID: 8411259
-
Combined use of biomarkers for detection of ovarian cancer in high-risk women.Tumour Biol. 2010 Jun;31(3):209-15. doi: 10.1007/s13277-010-0032-x. Tumour Biol. 2010. PMID: 20393825
-
New tumor markers: CA125 and beyond.Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. doi: 10.1111/j.1525-1438.2005.00441.x. Int J Gynecol Cancer. 2005. PMID: 16343244 Review.
-
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.J Clin Oncol. 2004 Oct 15;22(20):4059-66. doi: 10.1200/JCO.2004.03.091. Epub 2004 Sep 20. J Clin Oncol. 2004. PMID: 15381683
-
Status of tumor markers in ovarian cancer screening.J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. doi: 10.1200/JCO.2003.01.068. J Clin Oncol. 2003. PMID: 12743135 Review.
Cited by
-
The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer.Biomed Rep. 2016 Jul;5(1):41-44. doi: 10.3892/br.2016.682. Epub 2016 May 19. Biomed Rep. 2016. PMID: 27347403 Free PMC article.
-
Multiple biomarkers are more accurate than a combination of carbohydrate antigen 125 and human epididymis protein 4 for ovarian cancer screening.Obstet Gynecol Sci. 2022 Jul;65(4):346-354. doi: 10.5468/ogs.22017. Epub 2022 Apr 21. Obstet Gynecol Sci. 2022. PMID: 35443557 Free PMC article.
-
Demons-Meigs syndrome caused by a giant ovarian fibroma: A case report.Radiol Case Rep. 2024 Apr 13;19(7):2585-2589. doi: 10.1016/j.radcr.2024.03.016. eCollection 2024 Jul. Radiol Case Rep. 2024. PMID: 38645957 Free PMC article.
-
The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.J Clin Lab Anal. 2016 Sep;30(5):709-18. doi: 10.1002/jcla.21926. Epub 2016 Mar 17. J Clin Lab Anal. 2016. PMID: 26990679 Free PMC article.
-
Ovarian Cancer Biomarkers in the COVID-19 Era.Int J Environ Res Public Health. 2023 May 29;20(11):5994. doi: 10.3390/ijerph20115994. Int J Environ Res Public Health. 2023. PMID: 37297598 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials